Serenoa repens, also known as saw palmetto, is widely recognized for its beneficial properties, particularly effective in treating benign prostatic hyperplasia and androgenetic alopecia.

The fruits of this plant are a rich source of fatty acids and phytosterols, crucial for its therapeutic effects. However, taking Serenoa repens in the form of supplements can pose challenges, such as the degradation of sensitive nutrients and the difficulty in maintaining availability and effectiveness over time. These issues are effectively resolved using microcapsules developed by IPS, a leader in the supply of microencapsulated raw materials.

IPS's Serenoa microcapsules are produced through an aqueous phase coacervation process and provide a content of oil in the microcapsules between 80% and 90%.

The use of microencapsulation allows protecting the active ingredient from external factors that could compromise its effectiveness, such as oxidation and interaction with other components of formulations. The sizes of the microcapsules, ranging from 100 to 600 μm, are ideal for various product formats, especially hard capsules and orodispersible formulations. Additionally, the microencapsulation process prevents oil volatilization and preserves the concentration of fatty acids, crucial for inhibiting the enzyme 5α-reductase and reducing consumer inflammation.

Relying on an experienced supplier like IPS for the microencapsulation of active ingredients such as Serenoa repens is a strategic choice for supplement manufacturers. Consumers are guaranteed consistently effective supplements, and manufacturers can, on the other hand, benefit from a quality and versatile product, always keeping pace with new technological innovations.